<DOC>
	<DOCNO>NCT01315275</DOCNO>
	<brief_summary>The purpose study evaluate proportion patient 10 letter gain Best Corrected Visual Acuity ( BCVA ) 6 month current medical practice .</brief_summary>
	<brief_title>A Clinical Study Current Medical Practice Efficacy Safety Ranibizumab 0.5mg Diabetic Patients Presenting Visual Impairment Due Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female patient &gt; 18 year age sign informed consent Patients Type 1 Type 2 diabetes mellitus ( accord ADA WHO guideline ) HbA1c 10.0 % screening ( Visit 1 ) . Patients diet , exercise , and/or pharmacological treatment diabetes . Patients visual impairment due focal diffuse DME least one eye Central Retinal thickness OCT â‰¥ 250 micron central subfield BCVA score 78 39 letter , inclusively , use ETDRSlike visual acuity test chart test distance 4 meter ( approximate Snellen equivalent 20/32 20/160 ) Decrease vision due DME due cause , opinion investigator Medication management diabetes must stable within 3 month prior randomization expect remain stable course study . Ocular concomitant conditions/ disease Concomitant condition study eye could , opinion investigator , prevent improvement visual acuity study treatment Active intraocular inflammation ( grade trace ) either eye Any active infection ( e.g . conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) either eye History uveitis either eye Systemic condition treatment Active systemic infection History stroke &lt; 3 month Renal failure require dialysis renal transplant OR renal insufficiency creatinine level &gt; 2.0 mg/dl Untreated diabetes mellitus Blood pressure systolic &gt; 160 mmHg diastolic &gt; 100 mmHg Untreated hypertension Known hypersensitivity ranibizumab component ranibizumab formulation Others Women childbearing potential use contraception method ( ) specify study ( specify ) , well woman breastfeed Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>visual impairment</keyword>
	<keyword>macular edema</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>visual impairment due macular edema</keyword>
</DOC>